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Abstract 
 
The complement system plays an important role in the induction of inflammation. In this 
study we demonstrate that the initiation complexes of the lectin pathway, consisting of 
mannose-binding lectin (MBL) and associated serine proteases (MASPs) elicit Ca
2+
 signaling 
in cultured endothelial cells (HUVECs). This is in agreement with our previous results 
showing that the recombinant catalytic fragment of MASP-1 activates endothelial cells by 
cleaving protease activated receptor 4. Two other proteases, MASP-2 and MASP-3 are also 
associated with MBL. Earlier we showed that recombinant catalytic fragment of MASP-2 
cannot activate HUVECs, and in this study we demonstrate that the same fragment of MASP-
3 has also no effect. We find the same to be the case if we use recombinant forms of the N-
terminal parts of MASP-1 and MASP-2 which only contain non-enzymatic domains. 
Moreover, stable zymogen mutant form of MASP-1 was also ineffective to stimulate 
endothelial cells, which suggests that in vivo MASP-1 have the ability to activate endothelial 
cells directly as well as to activate the lectin pathway simultaneously. We show that among 
the components of the MBL-MASPs complexes only MASP-1 is able to trigger response in 
HUVECs and the proteolytic activity of MASP-1 is essential. Our results strengthen the view 
that MASP-1 plays a central role in the early innate immune response. 
 
 
 
Keywords: complement lectin pathway, MBL-associated serine proteases, endothelial cell, 
cell activation, protease activated receptor 
 
Abbreviations: HUVEC: human umbilical vein endothelial cell; MAPK: mitogen-activated 
protein kinase; MASP: MBL-associated serine protease; MASP-1cf: MASP-1 catalytic 
fragment; MAp: MBL-associated protein; MBL: mannan-binding lectin; PAR: protease 
activated receptor  
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1. Introduction 
 
The complement system is a major effector arm of innate immunity. Its main functions 
are labeling and eliminating invading pathogens and altered self structures, triggering 
inflammation, and modulating the adaptive immune response (Ricklin et al., 2010). This 
network of about 40 proteins includes recognition molecules, serine proteases, thioester 
containing molecules, cell-surface-receptors and regulators. The danger signals presented by 
invading pathogens (PAMP: pathogen associated molecular pattern) or by altered host cells 
(DAMP: damage or danger associated molecular pattern) are recognized by pattern 
recognition molecules. The lectin pathway of the complement system has at least five 
different pattern recognition molecules: mannose-binding lectin (MBL), H-, L- and M-ficolin 
(also named ficolin-3, -2, -1, respectively) (Thiel, 2007) and collectin-11 (also named 
collectin kidney 1) (Hansen et al., 2010). These molecules may recognize specific patterns of 
carbohydrate arrays on the surface of microorganisms, hence the name “lectin pathway”. The 
recognition event is converted into an enzymatic signal by serine proteases that are associated 
with the pattern recognition molecules. MBL and ficolins associate with three serine 
proteases: MASP (MBL-associated serine protease)-1, -2 and -3 (Matsushita and Fujita, 1992; 
Thiel et al., 1997; Dahl et al., 2001), and with two non-catalytic proteins MAp44 (Degn et al., 
2009; Skjoedt et al., 2010) and MAp19 (Stover et al., 1999; Takahashi et al., 1999). The 
composition and the stoichiometry of the MBL-MASPs and ficolin-MASPs complexes are 
not known but it seems likely that a number of different complexes exist in the plasma. When 
the pattern recognition molecules bind to the target structure, the zymogen serine proteases 
become activated. An Arg-Ile bond is cleaved in the activation loop, which results in 
conformational change in the serine protease domain. Recently, we have shown that MASP-1, 
the most abundant protease component of the lectin pathway, controls lectin pathway 
activation (Degn et al., 2012; Héja et al., 2012a; 2012b; Kocsis et al., 2010; Megyeri et al., 
2013). MASP-1 autoactivates and cleaves zymogen MASP-2, which then cleaves C4 and C2 
components (Kidmose et al., 2012). The resulting C3 convertase (C4b2a) is responsible for 
maintenance and amplification of the complement cascade.  
One of the most important functions of the complement cascade is to trigger 
inflammation. The split products released during complement activation (e.g. anaphylatoxins: 
C3a, C5a) activates leukocytes and endothelial cells through G protein-coupled receptors. 
Recently, we have discovered a new function of the complement system that may contribute 
to the pro-inflammatory effect of complement activation. MASP-1, like thrombin, is capable 
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of activating endothelial cells directly through cleavage of protease activated receptor 4 
(PAR4) (Megyeri et al., 2009). 
Endothelial cells, besides their obvious barrier function, have significant role in 
several important physiological and pathophysiological processes. Among others, endothelial 
cells coordinate inflammatory response involving a range of receptors and the capability of 
producing pro-inflammatory cytokines and adhesion molecules. Endothelial cell activation 
through PARs involves intracellular Ca
2+
-mobilization, which results in downstream 
cytoskeleton reorganization, mitogen-activated protein kinase (MAPK) activation and a shift 
in the pattern of gene expression. Thrombin and other agonist proteases, induce shape and 
permeability changes in the vascular endothelium and mobilize adhesive molecules to the cell 
surface promoting leukocyte rolling, adhesion and transendothelial migration. Previously we 
demonstrated that a recombinant catalytic fragment of MASP-1 (rMASP-1cf), which contains 
the serine protease (SP) domain and the two complement control protein (CCP) modules, 
cleaves PAR4 and elicits Ca
2+
 signaling, NF-κB nuclear translocation and p38 MAPK 
phosphorylation in human umbilical vein endothelial cells (HUVECs). Although the catalytic 
fragment is enzymatically equivalent to the full-length-molecule, it cannot bind to MBL or 
ficolins because the N-terminal three domains are missing. Under physiological conditions 
MASP-1 is a part of the MBL-MASPs complexes as well as part of ficolin-MASPs 
complexes. The complex formation between MASP-1 and MBL may change the accessibility 
of the active site of the protease for external substrates, like PARs. Moreover, it was shown 
earlier that MBL binds to endothelial cells (Oroszlán et al., 2007), and we cannot exclude the 
possibility that this binding modulates the effect of MASP-1 on the cells besides changing the 
local concentration of MASP-1 on the surface of the cells. It is therefore important to examine 
whether native MASPs in complexes with MBL are able to activate endothelial cells. 
In the present study we analyzed the effect of MBL-MASPs complexes on endothelial 
cells. We isolated MBL-MASPs complexes from human plasma and studied their ability to 
stimulate endothelial cells. We also wanted to show unambiguously that proteolytically 
inactive MASP-1 and the N-terminal non-catalytic regions of MASP-1/3 and MASP-2 are 
unable to activate cells. Moreover, we asked whether zymogen MASP-1 is able to activate 
endothelial cells similarly to activated MASP-1. Finally, we also examined whether the 
catalytic activity of the third protease component of the lectin pathway, MASP-3, exerts any 
effect on HUVECs. 
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2. Materials and Methods 
 
2.1. Materials 
CNBr-activated Sepharose 4B was from GE Healthcare. Coupling of mannan to 
CNBr-activated resin was performed according to the manufacturer’s instructions. All the 
other reagents were purchased from Sigma-Aldrich, unless otherwise stated. Lyophilized 
plasma C1 inhibitor (C1-inh, Berinert P) was from ZLB Behring, and it was further purified 
by cation-exchange chromatography (Source 15S column; GE Healthcare) and gel filtration 
(Sephadex 75 HiLoad 16/60; GE Healthcare). 
 
2.2. Recombinant MASP fragments  
DNA constructs of recombinant human MASP-1, and -2 catalytic fragments encoding 
the CCP1-CCP2-SP region (rMASPcf) were used for expression in E. coli as described 
(Ambrus et al., 2003). rMASP-2cf was prepared according to Gál et al. (Gál et al., 2005). The 
R448Q and S646A (precursor numbering) mutants of rMASP-1cf were made according to 
Megyeri et al. (Megyeri et al., 2013). Wild-type (wt) rMASP-1cf was produced as described 
by Dobó et al. (Dobó et al., 2008, 2009), but in the absence of benzamidine. The two-step 
purification procedure was performed in a single day in order to minimize degradation. 
The R448Q and the S646A variants of rMASP-1cf were prepared the same way as the 
wt enzyme, however in these cases the procedure yields the proenzymic (one-chain) form 
(Megyeri et al., 2013). The S646A mutant of rMASP-1cf at 100 g/mL was cleaved by 
rMASP-2 catalytic fragment (2.5 g/mL) by overnight incubation at room temperature to 
bring the enzyme into the two-chain form. After cleavage, the S646A mutant was further 
purified by repeating the anion exchange chromatographic step on a Source 30Q column to 
remove rMASP-2cf. We used rMASP-2cf to cleave rMASP-1cf S646A since the two can be 
separated due to their distinct chromatographic behavior. The procedure yielded an enzyme, 
which was in the active conformation, but due to the absence of the catalytic serine it had no 
catalytic activity. Since MASP-2 does not activate endothelial cells (Megyeri et al., 2009) 
traces of MASP-2 (if any) would not interfere with the cell activation assay. 
Wild type proenzymic rMASP-3cf was produced as previously described (Megyeri et 
al., 2013). Purified rMASP-3cf (400 g/mL) was activated by cleavage with rMASP-1cf (25 
g/mL) at 37 oC for 3 hours. In the next step rMASP-1cf were removed from the samples by 
cation exchange chromatography on a SP Sepharose High Performance (GE Healthcare) 
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column. The N-terminal fragments (CUB1-EGF-CUB2) of MASP-1 and MASP-2 were 
prepared as described by Paréj et al. (2014). 
 
2.3. Purification of MBL-MASPs complexes  
MBL-MASPs complexes were purified by a modified method described by Matsushita 
et al (Matsushita et al., 2000b).  Briefly: plasma samples were clotted by the addition 25 mM 
CaCl2 and filtered through muslin and the resulting serum was kept at -80
o
C until further 
usage.  Serum samples were then thawed and incubated overnight at 4
o
C with yeast mannan-
Sepharose 4B resin using 10 mM imidazole buffer (pH 6.0) containing 0.2 M NaCl, 20 mM 
CaCl2, 0.1 mg/ml Pefabloc, and 2% mannitol.  After washing the resin with the same buffer, 
the MBL-MASPs complexes were eluted from the mannan-beads using the above buffer 
containing 0.3 M mannose. The MBL and MASP-1 concentrations in the eluted samples were 
determined by sandwich-type immune-assays (see below) as previously described (Thiel et 
al., 2012; 2002).  
To increase the yield of the purified MBL-MASPs complexes we modified the 
protocol by adding 10 µg/ml recombinant MBL (Jensenius et al., 2003) to the serum samples 
before incubation with mannan-Sepharose 4B resin. After elution, the fractions were checked 
by TRIFMA and the appropriate fractions were pooled and concentrated on a spin 
concentrator and dialyzed against Hank's Balanced Salt Solution (HBSS) and kept at -80
o
C 
until use on endothelial cells. 
 
2.4. C1-inhibitor treatment 
 In some control experiments the activity of the plasma derived and recombinant 
MASP-1 was blocked by C1-inhibitor. The proteases were incubated with C1-inhibitor in a 
1:1 molar ratio at 37
o
C for 20 min before adding to the HUVECs. 
 
 
2.5. Western blot analysis of purified MBL-MASP complexes 
The Western blot analysis of the purified complexes was performed using the 
antibodies and the protocol described in detail in Degn et al. (Degn et al., 2010).  The rabbit 
antiserum towards MASP-1, Rabbit64, was raised against the 19 amino acid located on the C-
terminus of MASP-1, and thus recognizes the serine protease domain of MASP-1, also called 
the B chain. Images were taken by CCD camera (LAS-3000, Fuji) and analyzed by the 
software supplied with the camera.  
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2.6. Assay of the lectin pathway components in the purified complexes  
Concentration measurements of MASP-1 (Thiel et al., 2012), MASP-3 and MAp44 
(Degn et al., 2010), MASP-2 (Møller-Kristensen et al., 2003), MAp19 (Degn et al., 2011) and 
MBL (Thiel et al., 2002) in the purified complexes were carried out, as described previously. 
All assays are based on sandwich-type immunoassays performed in microtiter wells with the 
use of biotin-labeled detecting Abs followed by europium-labeled streptavidin. The amount of 
europium bound in the wells is subsequently measured by time-resolved fluorescence, and 
this assay type is therefore referred to as a time-resolved immunofluorimetric assay 
(TRIFMA). 
 
2.7. Preparation and culture of HUVECs and measurement of intracellular Ca
2+
 signaling by 
fluorescence microscopy 
The preparation and culture of endothelial cells, and the Ca
2+
-mobilization 
measurements were performed as described previously (Megyeri et al., 2009). Briefly, 
HUVECs were cultured in 96-well plates for 1 day then loaded with Fluo-4-AM (2 µM). 
Three photos were taken on an Olympus XM-10 camera as a base-line then the activator was 
added to the cells and the response was measured for 2 minutes. The maximum fluorescence 
intensity and the base-line fluorescence intensity were calculated, and the differences were 
compared to those of positive controls. 
 
2.8. Statistical analysis  
Data were compared using one-way ANOVA with Tukey’s post-test and Student’s t-
test (GraphPad Prism 4.02 software, GraphPad, http://www.graphpad.com/). A p-value less 
than 0.05 was considered significant. Data are presented as means ± SEM. 
 
3. Results 
 
3.1. Purification of MBL-MASPs complexes form human plasma 
To assess whether MBL-MASPs complexes can stimulate endothelial cells, we 
purified MBL-MASPs complexes from human plasma according to the original protocol of 
Matsushita et al. (Matsushita et al., 2000a) and measured the quantity of the yielded MBL and 
MASP-1 in the different fractions (data not shown). We found that MASP-1 co-eluted from 
the affinity column with MBL and the amount of MBL was proportional to the MASP-1 
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concentration. Unfortunately, this protocol was not able to yield sufficient amount of MASP-1 
for testing endothelial cell activation. In order to increase the yield of MBL-bound MASP-1, 
we added recombinant MBL (10 µg/ml) to the serum samples before incubation with the 
mannan-conjugated Sepharose 4B resin. While the original protocol yielded 8 µg MASP-1 
from 100 ml serum, the modified one allowed us to isolate 160 µg MASP-1 from the same 
volume of serum. Apparently, the addition of recombinant MBL shifted the equilibrium in 
such a way that the amount of MBL-MASPs complexes increased considerably at the expense 
of the ficolin-MASPs complexes. The purified complex was characterized by Western blot 
analysis after fractionation in reducing conditions and developing the membrane with rabbit 
antisera (Rabbit 64) towards MASP-1 that recognizes the MASP-1 B chain (Degn et al., 
2010). It is known that MASP-1 is readily activated and we also find here that zymogen 
MASP-1 is autoactivated after the purification and dialysis against the HBSS buffer and 
subsequent concentration of the samples (Fig. 1). 
On figure 1 we have marked the position of non-cleaved MASP-1 (MASP-1 zymogen) and 
the position of the protease domain, i.e. the B-chain (separated from the A chain since the 
SDS-PAGE was performed in reducing conditions), as well as a band representing a further 
degradation product, i.e. B´ chain. On the figure we have also marked the covalent complex 
that is formed between activated MASP-1 and C1-inhibitor. It can be seen on figure 1 that 
gradually more and more MASP-1 is activated during the dialysis and concentration steps.  
We also determined the concentration of the different effector molecules in the 
purified and concentrated samples, and compared these values to the average concentrations 
measured in the starting sera (Table 1). The purification resulted in an almost 50-fold 
enrichment of MASP-1 as well as of MAp44 (48-fold and 49-fold, respectively) in the 
samples, whereas in the case of MASP-3 we could only detect a 15-fold enrichment. MASP-
1, MAp44 and MASP-3 are three splice variants of the MASP1 gene sharing the same N-
terminal four domains (CUB1-EGF-CUB2-CCP1). Since the first three N-terminal domains 
(CUB1-EGF-CUB2) are responsible for the binding to MBL, we would have expected similar 
enrichment. We also see an elevation in the concentration of MASP-2 (21-fold), and MAp19 
shows a 10-fold enrichment compared to the reference value.  
 
3.2. MBL-MASPs complexes trigger Ca
2+
 -signaling in endothelial cells 
After purification of the MBL-MASPs complexes from human plasma we applied 
them to HUVECs and measured the Ca
2+
 signals by fluorescent microscopy. MBL-MASPs 
complexes containing 2 µM MASP-1 triggered intracellular Ca2+ increase in endothelial cells 
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in  a similar way to histamine (50 µM), which was used as a positive control (Fig. 2A). The 
kinetics of the MBL-MASPs-induced intracellular Ca
2+
 release is similar to what we have 
measured previously using recombinant MASP-1 catalytic fragment (rMASP-1cf) containing 
the serine protease domain and the two complement control protein modules (Megyeri et al., 
2009). The MBL-MASPs-induced Ca
2+
 signal was dose dependent correlating with the 
MASP-1 content of the MBL-MASPs complexes (Fig. 2B). rMBL in the same concentration 
as found in the purified MBL-MASPs complexes (32 µM) did not induce Ca2+ signals (Fig. 
3). If we pre-incubated the MBL-MASPs complexes with C1 inhibitor (C1-inh) in a 1:1 molar 
ratio the effect was inhibited (Fig. 3).  
 
3.3. Proteolytically inactive forms MASP-1 catalytic fragments do not activate endothelial 
cells 
MASP-1 circulates in zymogen (proenzyme) form in the blood and it autoactivates 
only when the recognition molecule of the complex binds to target surface. We wanted to 
investigate whether MASP-1, and consequently the lectin pathway of complement, needs to 
be activated for triggering pro-inflammatory signals on endothelial cells. Previously, we 
created a stable proenzyme rMASP-1cf (R448Q) molecule by mutating the activation loop 
arginine to glutamine  (Megyeri et al., 2013). This mutant cannot be cleaved by trypsin-like 
serine proteases and retains its one-chain proenzyme form. We added the zymogen rMASP-
1cf R448Q mutant to the cells and measured the Ca
2+
 signaling by fluorescent microscopy. 
The zymogen R448Q mutant did not trigger Ca
2+
 signals on HUVECs even at high 
concentration (2 µM) (Fig. 4A,B), whereas the wild type rMASP-1cf as well as the MBL-
MASPs complexes activated the cells. This indicates that MASP-1 needs to be in active form 
to be able to induce pro-inflammatory signaling on endothelial cells. 
As we have shown here using the MBL-MASPs complex and previously using the 
rMASP-1cf catalytic fragment (Megyeri et al., 2009), the effect of MASP-1 could be inhibited 
by pre-incubation with equimolar amount of C1-inh (Fig. 3). This suggested, but did not 
incontrovertibly prove that the proteolytic activity of MASP-1 is responsible for PAR4 
cleavage on endothelial cell surface. C1-inh forms a covalent complex with MASP-1 (Davis 
et al., 2008; Paréj et al., 2013), possibly distorting its structure and preventing the access of 
MASP-1 to their receptors. In order to unambiguously prove that the proteolytic activity of 
MASP-1 is responsible for cell activation, we created a proteolytically inactive form of 
MASP-1 catalytic fragment, which has the conformation of the active protease. We mutated 
the catalytic serine residue to alanine (S646A) as previously described (Megyeri et al., 2013) 
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and cleaved the R
448
-Ile
449 
activation bond by MASP-2. Thus, we produced a proteolytically 
inactive two-chain form of rMASP-1cf. After administration of the inactive rMASP-1cf 
(S646A) to HUVECs we could not detect any Ca
2+
-signals by fluorescent microscopy (Fig. 
4A,B). 
 
3.4. The N-terminal region of MASP-1 and MASP-2 do not activate endothelial cells 
The MBL-MASPs complexes, besides the full-length serine proteases, contain the 
non-catalytic splice products of the MASP1 and MASP2 genes, MAp44 and MAp19, 
respectively. These molecules consist of the N-terminal interacting domains of the MASPs. In 
order to prove that the N-terminal non-catalytic region of MASP-1 and MASP-2 do not 
activate endothelial cells, we incubated HUVECs with recombinant fragments containing the 
three N-terminal domains (CUB1-EGF-CUB2) of the proteases. These proteins showed no 
detectable effect on the cells (Fig. 3), even at high concentration, corroborating that the 
proteolytic activity of MASP-1 is the key factor for cell activation, and other domains of the 
MASPs do not interact with receptors. These experiments also very strongly suggest that the 
two non-catalytic MBL-associated proteins, MAp19 and MAp44 do not contribute to the 
direct cell-activating ability of the complexes. 
 
3.5. MASP-3 does not activate endothelial cells 
Besides MASP-1 the MBL-MASPs complexes contain two other proteases: MASP-2 
and MASP-3. We have previously shown that MASP-2 do not activate endothelial cells 
(Megyeri et al., 2009). In this study we also wanted to examine whether the proteolytic 
activity of MASP-3, the second most abundant protease of the lectin pathway, contributes to 
the pro-inflammatory effect. We produced the recombinant catalytic fragment (CCP1-CCP2-
SP) of MASP-3 (Megyeri et al., 2013). MASP-3, unlike MASP-1 and MASP-2, does not 
autoactivate but it can be activated by MASP-1 cleavage. We cleaved the rMASP-3cf by 
rMASP-1cf and carefully removed the traces of rMASP-1cf form the active rMASP-3cf 
sample. Endothelial cells were treated with activated rMASP-3cf and the Ca
2+
 response was 
assessed. rMASP-3cf did not activate the HUVECs even at high concentration implicating 
that MASP-1 is the exclusive activator of the endothelial cells among the components of the 
MBL-MASPs complexes (Fig 3).  
 
4. Discussion 
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The lectin pathway of the complement system is an important effector arm of the 
innate immunity. After the pattern recognition molecules bind to the activator structures, the 
associated serine proteases become activated and initiate the complement cascade resulting in 
several effector functions. One of the most important consequences of complement activation 
is the initiation of inflammation. In this work we have shown that MBL-MASPs complexes 
prepared from human plasma are able to directly activate endothelial cells. This is in good 
agreement with our previous results demonstrating that the catalytic fragment of MASP-1, 
containing the serine protease domain and the two complement control protein modules, 
cleaves protease activated receptor (PAR) 4 on the surface of endothelial cells and elicits Ca
2+
 
response. The Ca
2+
 signal in the endothelial cells was proportional to the MASP-1 content of 
the MBL-MASPs complexes suggesting that MASP-1 is the exclusive activator of the 
endothelial cells in this case. Indeed, we demonstrated that the other components of the 
complexes: MBL, MASP-2, MASP-3, and the N-terminal domains of the MASPs are unable 
to elicit any response in HUVECs by themselves. These results strengthen the view that the 
catalytic fragment of MASP-1 (rMASP-1cf) is enzymatically equivalent to the full-length 
molecule; the CUB1-EGF-CUB2 region does not influence the substrate specificity. The N-
terminal region, however, anchors the protease to the collagen-like stalks of the pattern 
recognition molecule, which might affect the accessibility of the serine protease domain to the 
potential substrates. This might especially concern the cell-surface substrates, such as 
receptors, where the accessibility is originally restricted. As our results demonstrate the MBL-
bound MASP-1 readily cleaves its substrate, the pattern recognition molecule does not restrict 
its proteolytic activity. On the contrary, the pattern recognition molecule can fix the protease 
near to the substrate ensuring an efficient local effect. In this respect it is important to note 
that MBL was shown to bind to HUVECs and this binding was increased upon LPS treatment  
(Oroszlán et al., 2007), however, in accordance with our present results, binding of 
uncomplexed (empty) MBL did not stimulate the endothelial cells. It seems plausible that in 
certain pathophysiological situation (e.g. bacterial infection, ischemia-reperfusion) endothelial 
cells express ligands for the pattern recognition molecules, which results in binding of the 
complexes, activation of MASP-1 and cleavage of cell-surface receptors. This pro-
inflammatory mechanism could be especially important, since MASP-1 directly activate the 
cells at the very beginning of the complement cascade preceding the generation of the 
anaphylatoxins. 
 Recently it has been shown that MASP-1 also activates hepatic stellate cells (Saeed et 
al., 2013). Although the mechanism is not clarified yet, it seems likely that MASP-1 cleaves 
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protease activated receptor on the hepatic cells. This phenomenon shows that the cell-
activating ability of MASP-1 is not confined to endothelial cells. 
Another recent paper reports that MBL induces cell death of proximal tubular 
epithelial cells (PTEC) during renal ischemia/reperfusion injury (IRI) without complement 
activation; i.e. no C3 deposition or C5b-9 complex formation was necessary for the cytotoxic 
effect (van der Pol et al., 2012). Although it was shown that MBL itself mediates cell death in 
PTEC cell culture, we cannot rule out the contribution of MASP-1 in the in vivo situation. 
During IRI, MBL in the serum specifically binds to the stressed cells, which is followed by 
the activation of associated MASP-1. The proteolytic action of MASP-1 on the PTE cells 
might contribute to the toxic effect immediately, preceding C3 and C5 convertase formation. 
This hypothesis might be checked in the future using MASP-1 specific inhibitors (Heja et al., 
2012a). 
 The effect of the MBL-MASPs complexes and that of rMASP-1cf can be abolished by 
C1-inh treatment. C1-inh is a serpin (serine protease inhibitor) that makes a covalent complex 
with the protease molecule, distorting its structure and preventing cleavage of further 
substrate molecules  (Beinrohr et al., 2007). We wanted to unambiguously exclude the 
possibility that the C1-inh mediated inhibition of the cell activating ability of MASP-1 is due 
to steric reasons; i.e. the complex formation with C1-inh simply prevents the binding the 
protease to the receptor and the lack of proteolytic activity plays no role in the inhibition. 
Neither the stable zymogen one-chain mutant form of rMASP-1cf (R448Q) nor the activation 
loop cleaved but proteolytically inactive mutant (S646A) was able to exert any effect on 
HUVECs. These results prove that the proteolytic activity of MASP-1 is essential for 
endothelial cell activation and the simple binding of MASP-1 to the receptor is not sufficient 
to provoke any response. 
The ineffectiveness of zymogen (R448Q) mutant may also confirm that MASP-1 
induced endothelial cell activation has an in vivo role, as in the absence of pathogen/danger 
associated molecular pattern (PAMP/DAMP), MASP-1 exists in a zymogen form and thus is 
incapable of activating endothelial cells. However, upon emergence of PAMPs/DAMPs, MBL 
and ficolins recognize these patterns leading to a rapid cleavage and activation of MASP-1, 
and this reaction is controlled by C1-inh. Anaphylatoxins are produced later in the 
complement cascade, and their formation is regulated by a large set of complement inhibitors 
beside C1-inh, such as C4BP, factor H, factor I, DAF etc., therefore, MASP-1 may be 
effective even when the production of anaphylatoxins are blocked. Moreover, MASP-1 and 
anaphylatoxins may have synergistic effects, which is out of the scope of this study. 
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 During this study we improved the yield of MBL-MASPs complexes when purifying 
from human serum. The original protocol yields only the native MBL-MASPs complexes, 
which contain only a fraction of the total MASPs content of the serum. Most of the MASPs 
and MAps are associated with the ficolins whose total concentration (781 nM) far exceeds 
that of MBL (48 nM) (Thiel et al. 2012). We supplemented the serum with 400 nM 
recombinant MBL which dramatically increased the yield of the associated proteins. Hence it 
is obvious that the MASPs and MAps can migrate between the recognition molecules and the 
system is in dynamic equilibrium. This equilibrium can be shifted by adding empty 
(uncomplexed) recognition molecules to the serum. It is interesting that although complete 
dissociation of the MBL-MASPs complexes can be achieved only in the presence of EDTA 
and high ionic strength (Thiel et al., 2000), the associated proteases can readily migrate 
between the recognition molecules in the normal human plasma. It may also be possible that 
when an empty pattern recognition molecule binds to the activator surface it can recruit 
MASPs form the serum to generate the initiation complex. Another alternative would be that 
in serum there is a surplus of MASPs that are not bound to pattern recognition molecules but 
may be bound if we add a much higher concentration of MBL. 
 In conclusion, we showed that MBL-MASPs complexes are able to activate 
endothelial cells via the proteolytic activity of MASP-1. Our results strengthen the view that 
MASP-1 plays a central role in the early innate immune response. After autoactivation it 
initiates the lectin pathway by activating MASP-2 and MASP-3, and it also has pro-
inflammatory activity by cleaving other substrates, such as protease activated receptor, high 
molecular weight kininogen (Dobó et al., 2011) and fibrinogen (Gulla et al., 2009; Hess et al., 
2012). In this way MASP-1 initiates a multi-faceted response against the possibly dangerous 
particles recognized by the pattern recognition molecules. 
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Figure legends 
 
Figure 1. MASP-1 autoactivates in the MBL-MASPs complexes during purification. 
MBL-MASPs complexes were purified on mannan-Sepharose from serum to which 
recombinant MBL had been added. The figure shows western blot analysis of reduced 
samples from the last steps of purification developed with Rabbit 64 antiserum recognizing 
MASP-1 B and B’ chains under reducing conditions. The MASP-1 zymogen disappears from 
the sample during dialysis and concentration and is found in the activated (two chain) form. 
Lane 1 is the sample after elution from the mannan-Sepharose 4B affinity column. Lane 2 is 
the sample after dialysis against HBSS buffer. Lane 3 is the sample after removing the 
precipitate formed during dialysis and Lane 4 is the concentrated stock used for experiments 
on endothelial cells.  Molecular weight markers are shown on the right hand side and the 
positions of the MASP-1 related bands are indicated on the left hand side. 
 
Figure 2. MBL-MASPs complexes trigger intracellular Ca
2+
- signaling in HUVECs. 
Intracellular Ca
2+
-signaling was measured by fluorescence microscopy in every 5 s for 115 s 
after activation of HUVECs loaded with Fluo-4 dye. MBL-MASPs complexes, and histamine 
as a positive control, were added at 15 s. A, Representative kinetic curves of calcium response 
in HUVEC triggered by 50 μM Histamine and MBL-MASPs complexes containing 2 μM 
MASP-1. Mean fluorescent measurements of 20 cells with SEM are plotted against time. B, 
Dose-dependent calcium response induced by MBL-MASPs complexes containing 0.2, 0.6 or 
2 μM MASP-1. Maximum green fluorescent values (mean of 20 cells) were normalized by the 
response to that of 50 μM Histamine. Means ± SEM of 3 independent experiments performed 
on HUVECs from different donors are presented. The significance compared to buffer control 
was calculated by one way ANOVA. ***: p< 0.001 ns: non significant.  
 
Figure 3. The Ca
2+
 mobilization ability of MBL-MASPs complexes, rMASP-1cf, MBL, 
rMASP-3cf and the N-terminal fragments of MASPs. The Ca
2+
 mobilization as the 
percentage of signal induced by histamine is shown. MBL-MASPs complexes containing 1 
μM MASP-1 were preincubated with equimolar amount of C1-inh before treatment of the 
cells. rMASP-3cf consists of the CCP1-CCP2-SP domains in the active conformation (see 
Materials and Methods). The N-terminal fragments of MASP-1 and -2 comprise the 
respective CUB1-EGF-CUB2 domains of the proteins. Maximum green fluorescent values 
(mean of 20 cells) in the percentage of histamine were calculated, and mean ± SEM of 3 
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independent experiments performed on HUVECs from different donors are presented. ***: p< 
0.001 ns: non significant. 
 
Figure 4. Proteolytically inactive MASP-1 catalytic fragments do not activate endothelial 
cells. The intracellular calcium signal triggered by zymogen R448Q rMASP-1cf (abbreviated 
as RQ-mutant) and catalytically inactive S646A rMASP-1cf (abbreviated as SA-mutant) was 
measured. The S646A fragment was brought into active conformation as described in the text. 
A, Representative kinetic curves of calcium response in HUVECs triggered by 2 μM wt, 
S646A or R448Q rMASP-1cf fragments. Thrombin (100 nM) was used as a positive control. 
Mean fluorescent measurements of 20 cells with SEM are plotted against time. B, Calcium 
mobilization of proteolytically inactive mutants S646A and R448Q are shown as the 
percentage of fluorescent signal induced by 100 nM thrombin. Means of maximum green 
fluorescent values of 20 cells were calculated and, mean ± SEM of 3 independent experiments 
performed on HUVECs from different donors are presented. ***: p< 0.001 ns: non 
significant. 
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Table 1. 
 
Table 1. Concentration of MBL-associated proteases (MASPs) and proteins (MAps) in plasma 
and in purified samples 
 
 MASP-1 MASP-3 MAp44 MASP-2 MAp19 
Initial conc. 
a
 (μg/ml)  9.6 4.6 1.4 0.3 NM
b 
Average conc. 
c
 (μg/ml) 11.0 5.0 1.6 0.4 0.4 
Purified sample conc. (μg/ml) 466.0 70.0 68.0 6.0 4.0 
Purified / initial conc. ratio
 48.5 15.2 48.6 20.0 NA
d 
Purified /average conc. ratio
 42.4 14.0 42.5 15.0 10.0 
a
 Measured from the starting plasma samples using TRIFMA assay.  
b
 NM, not measured 
c
 Average serum concentrations determined by Thiel et al. (Thiel et al., 2012) 
d 
NA, not applicable 
 
 
